Skip Navigation
NIH HHS News Release Logo
National Institute of Allergy and
Infectious Diseases (NIAID)
http://www.niaid.nih.gov

FOR IMMEDIATE RELEASE
Thursday, August 11, 2011

Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

MEDIA AVAILABILITY
Scientists Explain Unique Activity of TB Drug Pyrazinamide

WHAT:
Pyrazinamide has been used in combination with other drugs as a first-line treatment for people with tuberculosis (TB) since the 1950s, but exactly how the drug works has not been well understood. Now, researchers have discovered a key reason why the drug effectively shortens the required duration of TB therapy. The finding potentially paves the way for the development of new drugs that can help eliminate TB in an infected individual even more rapidly. The study was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and published online on August 11 in Science Express.

Unlike most first-line TB drugs, pyrazinamide does not directly kill Mycobacterium tuberculosis, the bacterium that causes TB, grown in a test tube; rather, the drug acts only on latent TB bacteria that exist in an acidic environment. From previous studies, the investigators knew that shortly after pyrazinamide enters latent M. tuberculosis in the body, the drug converts to its active form, pyrazinoic acid (POA). But they did not know how POA then killed the bacteria, thereby shortening the normal 9- to 12-month course of therapy by several months.

In this study, the researchers learned that once formed, POA binds to a vital bacterial cell protein, ribosomal protein S1 (RpsA), blocking RpsA from decoding M. tuberculosis DNA to create other proteins that keep the bacteria alive in the body. The investigators note that their results explain the mechanism of this enigmatic TB drug, which could assist researchers attempting to develop improved TB drug treatment regimens.

ARTICLE:
W Shi et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science Express DOI: 10.1126/science.1208813 (2011).

WHO:
Clifton E. Barry, Ph.D., chief of NIAID’s Tuberculosis Research Section, Laboratory of Clinical Infectious Diseases, and a co-author of the paper, is available to discuss this study.

CONTACT:
To schedule interviews, please contact Nalini Padmanabhan, (301) 402-1663, niaidnews@niaid.nih.gov.


NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at www.niaid.nih.gov.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH...Turning Discovery Into Health ®

back to top


Last Updated August 11, 2011

Last Reviewed August 10, 2011